In brief: Imugene; Cryptome
Monday, 17 January, 2005
Imugene (ASX: IMU) has been granted patent protection for its Receptor Mimic Technology (RMT) in the United States.
RMT uses non-pathogenic bacteria modified to express receptor mimics on their surface which bind to disease-causing toxins or viruses, preventing them from binding to the gut wall and being absorbed.
Imugene Managing Director, Dr Warwick Lamb said the patent grant covered RMT use in both animals and humans. Patent coverage will run until 2020.
Animal trials results boost Cryptome
Shares in Cryptome Pharmaceuticals (ASX:CRP) were up 13 per cent at time of writing, after the company announced that animal studies carried out in 5 guinea pigs show that its lead drug candidate, CR001, was well tolerated and reduced the tendency of blood to clot .
In standard assay tests on samples taken from the animals five minutes after administration of the drug, CR001 was found to delay the coagulation of blood by approximately 55 per cent.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
